Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Lateral Femoral Cutaneous Nerve Block (LFCN) in ACL Reconstruction With MacFL-type Lateral Tenodesis (RECUP- NCLC)

3 de noviembre de 2026 actualizado por: GCS Ramsay Santé pour l'Enseignement et la Recherche

The goal of this randomized clinical trial is to evaluate whether adding an ultrasound-guided lateral femoral cutaneous nerve (LFCN) block to a standard regional analgesia protocol improves postoperative recovery in patients undergoing anterior cruciate ligament (ACL) reconstruction combined with MacIntosh-type lateral extra-articular tenodesis.

The main question the study aims to answer is whether adding an LFCN block to an adductor canal block (ACB) and an iPACK block improves the quality of postoperative recovery, as measured by the Quality of Recovery-15 (QoR-15) score at 24 hours after surgery.

The study will also assess:

  • Preservation of quadriceps function, assessed by the ability to perform a straight leg raise (SLR).
  • Postoperative pain at the lateral thigh graft harvest site and knee, at rest and during mobilization.
  • Cumulative oral opioid consumption during the first 48 hours after surgery.
  • Incidence of postoperative nausea and vomiting (PONV).
  • Time to first postoperative ambulation.
  • Patient satisfaction with analgesic management.

Adverse events and complications related to regional anesthesia, including sensory disturbances, hematoma, infection, and signs of local anesthetic systemic toxicity.

Participants will be randomly assigned in a 1:1 ratio to one of two treatment groups. All participants will undergo ACL reconstruction combined with MacIntosh-type lateral extra-articular tenodesis and will receive an ACB and an iPACK block. Participants in the experimental group will additionally receive an ultrasound-guided LFCN block.

Postoperative assessments will include QoR-15, pain scores, opioid consumption, PONV, quadriceps function, ambulation, patient satisfaction, and safety assessments during the first 48 hours after surgery and at 1 month. The primary outcome will compare the QoR-15 score at 24 hours between the two groups, with an 8-point difference considered clinically meaningful.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

108

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Quincy-sous-Sénart, Francia
        • Hôpital Privé Claude Galien
        • Contacto:
      • Évry, Francia

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 60 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adult patients aged 18 to 60 years;
  • Presenting a primary anterior cruciate ligament (ACL) tear;
  • Scheduled for ACL reconstruction associated with MacIntosh-type lateral extra-articular tenodesis (or equivalent technical variant using an iliotibial band 'ITB' graft);
  • Surgery to be performed under general anesthesia;
  • Planned management in outpatient surgery or short-stay hospitalization after the operation;
  • Understanding the validated French version of the QoR-15 questionnaire;
  • Having given their informed consent to participate in the study;
  • Patients affiliated with or benefiting from a social security scheme.

Exclusion Criteria:

  • Patients having allergy to local anesthetics or a contraindication to peripheral nerve blocks;
  • Patients having neuropathy of the lower limbs;
  • Patients having coagulation disorders or on major anticoagulation;
  • Patients suffering from chronic pain that requires more than 30 mg morphine-equivalents per day;
  • Patients undergoing revision ACL reconstruction;
  • Patients with pre-existing hypoesthesia of the lateral thigh (e.g. known meralgia paresthetica);
  • Patients unable to complete the questionnaires or expressing refusal to participate;
  • Pregnant women, women of childbearing age without effective contraception), or women breastfeeding;
  • Protected adults under guardianship, curatorship or other legal protection, deprived of liberty or under guardianship or curatorship, or unable to give consent.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: ACB + iPACK + LFCN Block

Participants will undergo anterior cruciate ligament reconstruction combined with MacIntosh-type lateral extra-articular tenodesis. They will receive an adductor canal block (ACB) and an iPACK block as the standard regional analgesia protocol, with the addition of an ultrasound-guided lateral femoral cutaneous nerve (LFCN) block.

Ultrasound-guided adductor canal block administered as part of the standard regional analgesia protocol for ACL reconstruction with MacIntosh-type lateral extra-articular tenodesis.

Ultrasound-guided iPACK block (infiltration between the popliteal artery and the posterior capsule of the knee) administered as part of the standard regional analgesia protocol.

Ultrasound-guided lateral femoral cutaneous nerve (LFCN) block administered in addition to the adductor canal block and iPACK block in the experimental arm.

Comparador activo: ACB + iPACK

Participants will undergo anterior cruciate ligament reconstruction combined with MacIntosh-type lateral extra-articular tenodesis. They will receive an adductor canal block (ACB) and an iPACK block without an additional lateral femoral cutaneous nerve (LFCN) block.

Ultrasound-guided adductor canal block administered as part of the standard regional analgesia protocol for ACL reconstruction with MacIntosh-type lateral extra-articular tenodesis.

Ultrasound-guided iPACK block (infiltration between the popliteal artery and the posterior capsule of the knee) administered as part of the standard regional analgesia protocol.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Quality of Recovery (QoR-15) Score
Periodo de tiempo: 24 hours after surgery

The quality of postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 score ranges from 0 to 150, with higher scores indicating better quality of recovery. The score will be assessed preoperatively before administration of regional anesthesia and again 24 hours after surgery. The primary analysis will compare the QoR-15 score at 24 hours between the experimental and active comparator groups. An 8-point difference between groups is considered the minimal clinically important difference.

24 hours after surgery

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Preservation of Quadriceps Function
Periodo de tiempo: 24 hours after surgery

Quadriceps function will be assessed by the ability to perform a straight leg raise (SLR) at 24 hours postoperatively.

24 hours after surgery
Postoperative Lateral Thigh and Knee Pain
Periodo de tiempo: 6, 24, and 48 hours after surgery

Pain intensity at the lateral thigh graft harvest site and knee will be assessed at rest and during mobilization using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst pain imaginable).

6, 24, and 48 hours after surgery
Cumulative Postoperative Opioid Consumption
Periodo de tiempo: Day 0, Day 1, and Day 2 after surgery

Total oral opioid consumption will be recorded and converted to morphine milligram equivalents (MME).

Day 0, Day 1, and Day 2 after surgery
Postoperative Nausea and Vomiting
Periodo de tiempo: Day 0, Day 1, and Day 2 after surgery

The incidence of postoperative nausea and vomiting (PONV) will be recorded during the postoperative period.

Day 0, Day 1, and Day 2 after surgery
Time to First Postoperative Ambulation
Periodo de tiempo: Day 1 after surgery

Time from surgery to first postoperative ambulation will be recorded in hours.

Day 1 after surgery
Patient Satisfaction With Analgesic Management
Periodo de tiempo: Day 1 and Day 2 after surgery

Patient satisfaction with postoperative analgesic management will be assessed using a 5-point Likert scale.

Day 1 and Day 2 after surgery
Safety and Adverse Events Related to Regional Anesthesia
Periodo de tiempo: Day 1 and 1 month after surgery

Adverse events and complications potentially related to regional anesthesia will be recorded, including hypoesthesia or paresthesia of the lateral thigh, abnormal sensory disturbances, hematoma at the LFCN block site, infection, and signs of local anesthetic systemic toxicity.

Day 1 and 1 month after surgery

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Yoann ELMALEH, Hôpital Privé Claude Galien

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de noviembre de 2027

Finalización del estudio (Estimado)

1 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

3 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Publicado por primera vez (Actual)

9 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

3 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir